Galectin Therapeutics Inc. (GALT)

[biotech2010]

New data presented at EASL presents valid reason for lack of significance in 8 mg/kg dose in CX trial, it was patient selection, not GR-MD-02:

"...Secondly, an evaluation of GR-MD-02 blood levels provided an explanation for the reduced efficacy response observed in the higher GR8 (8 mg/Kg) dose group. In the GR2 (2 mg/Kg) dose group, the blood levels (or total exposure to the drug as measured by area under the concentration-time curve) were tightly grouped. In contrast, there was a broad distribution of higher drug exposures in the GR8 group. Approximately half of the patients who received GR8 had GR-MD-02 blood concentration levels that had risen to a range where a reduced efficacy effect in the liver had been noted at very high doses in the NASH animal models."

http://globenewswire.com/news-release/2018/04/16/1471947/0/en/Galectin-Therapeutics-Late-Breaker-Presentation-at-The-International-Liver-Congress-Reinforces-and-Extends-the-Positive-Effects-of-GR-MD-02-in-Patients-With-NASH-Cirrhosis.html